Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD1”

2,786 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 2,786 results

Testing effectiveness (Phase 2)Study completedNCT03866967
What this trial is testing

Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma

Who this might be right for
Nasopharyngeal Carcinoma
Akeso 130
Large-scale testing (Phase 3)Study completedNCT01866319
What this trial is testing

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

Who this might be right for
Melanoma
Merck Sharp & Dohme LLC 834
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07022301
What this trial is testing

Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy

Who this might be right for
Small Cell Lung Cancer Extensive StageResistance to Immunotherapy
First Affiliated Hospital of Wannan Medical College 25
Testing effectiveness (Phase 2)Study completedNCT03463681
What this trial is testing

CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma

Who this might be right for
Metastatic Renal Cell Carcinoma
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 49
Testing effectiveness (Phase 2)UnknownNCT03993626
What this trial is testing

A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer

Who this might be right for
Colorectal Neoplasms Malignant
Celleron Therapeutics Ltd. 55
Not applicableUnknownNCT06335147
What this trial is testing

PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer

Who this might be right for
Metastatic Colon Cancer
Henan Cancer Hospital 23
Not applicableLooking for participantsNCT06887348
What this trial is testing

Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

Who this might be right for
MelanomaMetastatic MelanomaAdvanced Solid Tumor+1 more
Replimune Inc. 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT04295317
What this trial is testing

PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery

Who this might be right for
Intrahepatic Cholangiocarcinoma
Shanghai Zhongshan Hospital 65
Post-approval studies (Phase 4)UnknownNCT04040491
What this trial is testing

PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma

Who this might be right for
Peripheral T-cell Lymphoma
Mingzhi Zhang 100
Testing effectiveness (Phase 2)UnknownNCT03972722
What this trial is testing

Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer

Who this might be right for
Cervical Cancer
Guangzhou Gloria Biosciences Co., Ltd. 89
Not applicableLooking for participantsNCT06904131
What this trial is testing

A Phase I Clinical Trial of CAR-T Cells for Advanced Gynecological Solid Tumors

Who this might be right for
Gynecological Solid Tumors
Obstetrics & Gynecology Hospital of Fudan University 20
Early research (Phase 1)Study completedNCT03547037
What this trial is testing

Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers

Who this might be right for
Neoplasm
Janssen Pharmaceutical K.K. 22
Early research (Phase 1)WithdrawnNCT04605614
What this trial is testing

64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression

Who this might be right for
Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
City of Hope Medical Center
Not applicableNot Yet RecruitingNCT06682247
What this trial is testing

A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
Feng Wang 200
Testing effectiveness (Phase 2)Looking for participantsNCT06635785
What this trial is testing

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
OncoC4, Inc. 204
Not applicableLooking for participantsNCT06154668
What this trial is testing

Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients

Who this might be right for
Melanoma
University Hospital, Grenoble 707
Testing effectiveness (Phase 2)Looking for participantsNCT06981325
What this trial is testing

Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients

Who this might be right for
Basal Cell Carcinoma (BCC)First Line Treatment
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 34
Early research (Phase 1)UnknownNCT03468751
What this trial is testing

Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Henlix, Inc 30
Not applicableActive Not RecruitingNCT06796231
What this trial is testing

Efficacy of PD-1 Monoclonal Antibody in the Treatment of Phaeohyphomycosis

Who this might be right for
Phaeohyphomycosis
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 1
Not applicableLooking for participantsNCT06874257
What this trial is testing

Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade

Who this might be right for
AML (Acute Myelogenous Leukemia)
IRCCS Azienda Ospedaliero-Universitaria di Bologna 20
Load More Results